J.E. Debreczeni

AstraZeneca (United Kingdom) — United Kingdom

Materials Science · Physical Sciences

36h-index5.5kcitations158works4.82yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Enzyme Structure and Function(22), Peptidase Inhibition and Analysis(15), Protein Kinase Regulation and GTPase Signaling(14), Particle physics theoretical and experimental studies(13), Cancer Mechanisms and Therapy(12)

Publications157 total

Identification of novel, potent, and selective JAK2V617F inhibitors
Blood·2025Open Access
Development and characterization of a potent and selective BLIMP1 protac as a novel, first-in-class therapy for multiple myeloma
Blood·2025Open Access
146 (PB134): First disclosure of AZD3470, a highly potent MTA-cooperative PRMT5 inhibitor in PRIMROSE and PRIMAVERA clinical studies
European Journal of Cancer·2024· 1 cited
Discovery and <i>In Vivo</i> Efficacy of AZ-PRMT5i-1, a Novel PRMT5 Inhibitor with High MTA Cooperativity
Journal of Medicinal Chemistry·2024· 18 citedOpen Access
Cryo-EM structure determination of small therapeutic protein targets at 3 Å-resolution using a rigid imaging scaffold
Proceedings of the National Academy of Sciences·2023· 45 citedOpen Access
Correction to “Discovery of a Thiadiazole–Pyridazine-Based Allosteric Glutaminase 1 Inhibitor Series That Demonstrates Oral Bioavailability and Activity in Tumor Xenograft Models”
Journal of Medicinal Chemistry·2023
The <i>CCP</i>4 suite: integrative software for macromolecular crystallography
Acta Crystallographica Section D Structural Biology·2023· 760 citedOpen Access
Abstract 3088: Identification of a novel series of MTAP-selective PRMT5 inhibitors, and first disclosure of AZ-PRMT5i-1
Cancer Research·2023· 3 cited
Rigidified Scaffolds for 3 Angstrom Resolution Cryo-EM of Small Therapeutic Protein Targets
2022· 6 citedOpen Access
Cryo-EM: The Resolution Revolution and Drug Discovery
SLAS DISCOVERY·2020· 73 citedOpen Access
KRAS-specific inhibition using a DARPin binding to a site in the allosteric lobe
Nature Communications·2019· 93 citedOpen Access
Abstract 1647: Discovery of AZD0364, a potent and selective oral inhibitor of ERK1/2 that is efficacious in both monotherapy and combination therapy in models of NSCLC
Cancer Research·2018· 1 cited
Structure and characterization of a high affinity C5a monoclonal antibody that blocks binding to C5aR1 and C5aR2 receptors
mAbs·2017· 34 citedOpen Access
A High-Throughput Screening Triage Workflow to Authenticate a Novel Series of PFKFB3 Inhibitors
SLAS DISCOVERY·2017· 14 citedOpen Access
Structural and functional characterization of a DARPin which inhibits Ras nucleotide exchange
Nature Communications·2017· 105 citedOpen Access
Human KRAS in complex with darpin K27
2017
Structure-Guided Discovery of Potent and Selective Inhibitors of ERK1/2 from a Modestly Active and Promiscuous Chemical Start Point
Journal of Medicinal Chemistry·2017· 52 citedOpen Access
Human Erk2 with an Erk1/2 inhibitor
2017
Ligand complex structures in protein crystallography
Acta Crystallographica Section D Structural Biology·2017· 1 citedOpen Access
A study of the reactivity of S<sup>(VI)</sup>–F containing warheads with nucleophilic amino-acid side chains under physiological conditions
Organic & Biomolecular Chemistry·2017· 156 cited
page 1 of 8Next →

Frequent Co-authors

Stefan Knapp(14), Alex N. Bullock(9), P. Achard(7), J. Alcaraz Maestre(7), G. Alemanni(7), J. Allaby(7), A. Aloisio(7), H. Anderhub(7), V.P. Andreev(7), F. Anselmo(7), A. Arefiev(7), T. Azemoon(7), P. Bagnaia(7), A. Bajo(7), G. Baksay(7), L. Baksay(7), S.V. Baldew(7), S. Banerjee(7), Sw. Banerjee(7), A. Barczyk(7)